Denovo Biopharma

company

About

Denovo Biopharma is a privately held biotech company providing a novel biomarker solution to personalize drug development.

  • 1 - 10

Details

Last Funding Type
Series D
Last Funding Money Raised
¥300M
Industries
Biopharma,Biotechnology,Health Care
Founded date
Jan 1, 2011
Number Of Employee
1 - 10
Operating Status
Active

Denovo Biopharma is a privately held biotech company providing a novel biomarker solution to personalize drug development. The core technology is the industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples. This technology is especially useful for late stage clinical drugs that have completed trials with unsatisfactory efficacy. By identifying biomarkers correlated to patients' responsiveness to drug candidates retrospectively, our technology enables biotech and pharmaceutical companies to design new clinical trials in a targeted patient population to achieve significant efficacy and/or less adverse effects. Our platform can be broadly applied to biomarker discovery in many therapeutic areas, such as oncology, metabolic, cardiology, immunology and neurology.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
¥300M
Denovo Biopharma has raised a total of ¥300M in funding over 2 rounds. Their latest funding was raised on Dec 10, 2020 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 10, 2020 Series D ¥300M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Denovo Biopharma is funded by 1 investors. Zhejiang Silicon Paradise Asset Management Group are the most recent investors.
Investor Name Lead Investor Funding Round
Zhejiang Silicon Paradise Asset Management Group Series D